Cardiovascular Diseases in Patients After Hematopoietic Stem Cell Transplantation: Systematic Review and Meta-Analysis Publisher Pubmed



Alizadehasl A¹ ; Ghadimi N¹ ; Hosseinifard H² ; Roudini K³ ; Emami AH⁴ ; Ghavamzadeh A⁵ ; Khodaamorzideh D¹
Source: Current Research in Translational Medicine Published:2023

Abstract

Background: Hematopoietic Stem Cell Transplantation (HSCT), is performed to treat many malignancies such as autologous or allogenic. Despite the success of this method in treating patients, - sometimes some HSCT recipients face problems such as cardiovascular complications. Therefore, this systematic review and meta-analysis aimed to evaluate the prevalence of cardiovascular complications in post-transplant patients. Method: In order to review the published studies, we examined PubMed, MEDLINE, Cochrane Library, Scopus, and web of science databases from the beginning to the end of January 2022, and we used tools by the Newcastle–Ottawa Scale to evaluate the quality of the studies. Result: In this study, 37 articles were included in the meta-analysis and 30,957 patients were examined. Also, the mean age of patients was 35.37 years. Based on the results of the meta-analysis, the prevalence of cardiovascular disease (CVD), was 16.84%. In addition, other complications related to CVD which include Arrhythmias, Congestive Heart Failure (CHF), Hypertension, stroke, and mortality were examined in patients who had hematopoietic stem cell transplantation and the resulting amounts were 3.91%, 3.66, 17.71, 0.22%, and 1.53%, respectively. Conclusion: This study showed that the prevalence of cardiovascular disease after hematopoietic stem cell transplantation is high and needs special attention. © 2022 Elsevier Masson SAS